J Korean Endocr Soc.  2006 Dec;21(6):460-475.

Evaluation and Treatment of Adult Growth Hormone Deficiency: An American Endocrine Society Clinical Practice Guideline

• Kim SW
• Chung YS
• Lee EJ
• Kim SY

Abstract

No abstract available.

MeSH Terms

Adult*
Growth Hormone*
Humans
Growth Hormone

Reference

1. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958. 18:901–903.

2. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab. 2001. 86:1868–1870.

3. Cohen LE, Radovick S. Molecular basis of combined pituitary hormone deficiencies. Endocr Rev. 2002. 23:431–442.

4. Wajnrajch MP, Gertner JM, Harbison MD, Chua SC Jr, Leibel RL. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet. 1996. 12:88–90.

5. Mantovani G, Maghnie M, Weber G, DeMenis E, Brunelli V, Cappa M, Loli P, Beck-Peccoz P, Spada A. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type Ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab. 2003. 88:4070–4074.

6. Cacciari E, Zucchini S, Ambrosetto P, Tani G, Carla G, Cicognani A, Pirazzoli P, Sganga T, Balsamo A, Cassio A. Empty sella in children and adolescents with possible hypothalamic-pituitary disorders. J Clin Endocrinol Metab. 1994. 78:767–771.

7. Nicolson A, Toogood AA, Rahim A, Shalet SM. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol (Oxf). 1996. 44:311–316.

8. Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab. 2000. 85:1789–1793.

9. Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 1986. 62:1173–1179.

10. Arafah BM, Kailani SH, Nekl KE, Gold RS, Selman WR. Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas. J Clin Endocrinol Metab. 1994. 79:348–354.

11. Webb SM, Rigla M, Wagner A, Oliver B, Bartumeus F. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metab. 1999. 84:3696–3700.

12. Feigl GC, Bonelli CM, Berghold A, Mokry M. Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg. 2002. 97:415–421.

13. Snyder PJ, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med. 1986. 81:457–462.

14. Aimaretti G, Ambrosio MR, Di Somma C, Gasperi M, Cannavo S, Scaroni C, Fusco A, Del Monte P, De Menis E, Faustini-Fustini M, Grimaldi F, Logoluso F, Razzore P, Rovere S, Benvenga S, Degli Uberti EC, De Marinis L, Lombardi G, Mantero F, Martino E, Giordano G, Ghigo E. Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab. 2005. 90:6085–6092.

15. Vahl N, Jorgensen JO, Jurik AG, Christiansen JS. Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. J Clin Endocrinol Metab. 1996. 81:2209–2215.

16. Aimaretti G, Baffoni C, DiVito L, Bellone S, Grottoli S, Maccario M, Arvat E, Camanni F, Ghigo E. Comparisons among old and new provocative tests of GH secretion in 178 normal adults. Eur J Endocrinol. 2000. 142:347–352.

17. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab. 2003. 88:95–102.

18. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002. 87:2067–2079.

19. Chung YS, Kim HM, Lee EJ, Chung JH, Lee KM, Park SW, Cho HK, Lee HC, Huh KB, Park YK, Kim HS, Lee JH. Growth hormone secretory capacity of Korean adults. Korean J Med. 1994. 47:305–312.

20. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL, Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab. 1999. 84:2013–2019.

21. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab. 2002. 87:477–485.

22. GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000. 85:3990–3993.

23. Hartman ML. The Growth Hormone Research Society consensus guidelines for the diagnosis and treatment of adult GH deficiency. Growth Horm IGF Res. 1998. 8:suppl A. 25–29.

24. Sonksen PH, Christiansen JS. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Growth Horm IGF Res. 1998. 8:suppl B. 89–92.

25. Beshyah SA, Freemantle C, Thomas E, Rutherford O, Page B, Murphy M, Johnston DG. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf). 1995. 42:179–189.

26. Hoffman DM, O'Sullivan AJ, Freund J, Ho KK. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J Clin Endocrinol Metab. 1995. 80:72–77.

27. Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L, Isaksson OG. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993. 76:309–317.

28. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH, Russell-Jones D. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab. 1999. 84:2596–2602.

29. al-Shoumer KA, Gray R, Anyaoku V, Hughes C, Beshyah S, Richmond W, Johnston DG. Effects of four years' treatment with biosynthetic human growth hormone (GM) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol (Oxf). 1998. 48:795–802.

30. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol. 1991. 70:688–694.

31. Janssen YJ, Doornbos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab. 1999. 84:279–284.

32. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 1997. 82:2877–2884.

33. Svensson J, Sunnerhagen KS, Johannsson G. Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab. 2003. 88:2061–2069.

34. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol. 1991. 70:695–700.

35. Elgzyri T, Castenfors J, Hagg E, Backman C, Thoren M, Bramnert M. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency. Clin Endocrinol (Oxf). 2004. 61:113–122.

36. Jorgensen JO, Thuesen L, Muller J, Ovesen P, Skakkebaek NE, Christiansen JS. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol. 1994. 130:224–228.

37. Woodhouse LJ, Asa SL, Thomas SG, Ezzat S. Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab. 1999. 84:4570–4577.

38. Kim EH, Chon S, Koh KP, Oh SJ, Woo JT, Kim SW, Kim JW, Kim YS. The one year effects of growth hormone replacement on the body composition in the normal adults. J Kor Soc Endocrinol. 2004. 19:303–319.

39. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 1994. 78:669–674.

40. Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab. 2004. 89:1124–1130.

41. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993. 129:201–206.

42. Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Corneli G, Ghigo E, Lombardi G. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab. 1999. 84:1919–1924.

43. Hyer SL, Rodin DA, Tobias JH, Leiper A, Nussey SS. Growth hormone deficiency during puberty reduces adult bone mineral density. Arch Dis Child. 1992. 67:1472–1474.

44. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 1997. 137:240–245.

45. Vestergaard P, Jorgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Weeke J, Andersen M, Conceicao FL, Nielsen TL, Mosekilde L. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas--a case-control study. Clin Endocrinol (Oxf). 2002. 56:159–167.

46. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001. 16:398–405.

47. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med. 1996. 125:883–890.

48. Hansen TB, Brixen K, Vahl N, Jorgensen JO, Christiansen JS, Mosekilde L, Hagen C. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab. 1996. 81:3352–3359.

49. Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol (Oxf). 1995. 42:627–633.

50. Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson BA. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 1996. 81:2865–2873.

51. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res. 2002. 17:1081–1094.

52. Drake WM, Rodriguez-Arnao J, Weaver JU, James IT, Coyte D, Spector TD, Besser GM, Monson JP. The influence of gender on the short and long-term effects of growth hormone replacementon bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol (Oxf). 2001. 54:525–532.

53. Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol (Oxf). 2004. 60:568–575.

54. Olney RC. Regulation of bone mass by growth hormone. Med Pediatr Oncol. 2003. 41:228–234.

55. Teegarden D, Proulx WR, Martin BR, Zhao J, McCabe GP, Lyle RM, Peacock M, Slemenda C, Johnston CC, Weaver CM. Peak bone mass in young women. J Bone Miner Res. 1995. 10:711–715.

56. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J Pediatr Endocrinol Metab. 2003. 16:suppl 2. 327–335.

57. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf). 2004. 60:175–184.

58. Drake WM, Carroll PV, Maher KT, Metcalfe KA, Camacho-Hubner C, Shaw NJ, Dunger DB, Cheetham TD, Savage MO, Monson JP. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab. 2003. 88:1658–1663.

59. Mukherjee A, Attanasio AF, Shalet SM. Skeletal requirements for optimal growth hormone replacement in the transitional years. Growth Horm IGF Res. 2003. 13:suppl A. S130–S135.

60. Underwood LE, Attie KM, Baptista J. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab. 2003. 88:5273–5280.

61. Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab. 2005. 90:3946–3955.

62. Woo JT, Kim DY, Kim SW, Yang IM, Kim JW, Kim YS, Kim KW, Choi YK, Park JE. Effects of human growth hormone treatment in healthy older female. J Kor Soc Endocrinol. 1992. 7:352–357.

63. Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, Davies JS. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol (Oxf). 2002. 56:493–501.

64. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascularrisk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab. 2004. 89:2192–2199.

65. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000. 133:111–122.

66. Sesmilo G, Miller KK, Hayden D, Klibanski A. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab. 2001. 86:5774–5781.

67. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wuster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metb. 1999. 84:3929–3935.

68. Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson BA, Strasburger CJ. Adult Growth Hormone Deficiency Study Group. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab. 1997. 82:82–88.

69. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab. 2002. 87:3650–3655.

70. Kearney T, de Gallegos CN, Proudler A, Parker K, Anayaoku V, Bannister P, Venkatesan S, Johnston DG. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects. Metabolism. 2003. 52:50–59.

71. Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest. 2004. 113:25–27.

72. Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previouslyuntreated GH-deficient adults. Eur J Endocrinol. 2003. 149:511–519.

73. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002. 87:2121–2127.

74. Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab. 1995. 80:153–159.

75. Yuen K, Cook D, Ong K, Chatelain P, Fryklund L, Gluckman P, Ranke MB, Rosenfeld R, Dunger D. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults. Clin Endocrinol (Oxf). 2002. 57:333–341.

76. Leonsson M, Hulthe J, Oscarsson J, Johannsson G, Wendelhag I, Wikstrand J, Bengtsson BA. Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf). 2002. 57:751–759.

77. Markussis V, Beshyah SA, Fisher C, Parker KH, Nicolaides AN, Johnston DG. Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur J Endocrinol. 1997. 136:157–164.

78. Murata M, Kaji H, Mizuno I, Sakurai T, Iida K, Okimura Y, Chihara K. A study of carotid intima-media thickness in GH-deficient Japanese adults during onset among adults andchildren. Eur J Endocrinol. 2003. 148:333–338.

79. Colao A, Di Somma C, Filippella M, Rota F, Pivonello R, Orio F, Vitale G, Lombardi G. Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf). 2004. 61:360–366.

80. Pfeifer M, Verhovec R, Zizek B. Growth hormone (GH) and atherosclerosis: changes in morphology and function of major arteries during GH treatment. Growth Horm IGF Res. 1999. 9:suppl A. 25–30.

81. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab. 1999. 84:453–457.

82. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998. 128:262–269.

83. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol. 2004. 151:suppl 1. S93–S101.

84. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation. 2003. 108:2648–2652.

85. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990. 336:285–288.

86. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001. 357:425–431.

87. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 1997. 46:75–81.

88. Erfurth EM, Bulow B, Nordstrom CH, Mikoczy Z, Hagmar L, Stromberg U. Doubled mortality rate in irradiated patients reoperated for regrowth of a macroadenoma of the pituitary gland. Eur J Endocrinol. 2004. 150:497–502.

89. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab. 2000. 85:1420–1425.

90. Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, Lamberts SW, Erfurth EM, Webb SM, Ross RJ, Chihara K, Henrich G, Herschbach P, Attanasio AF. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab. 2004. 89:1684–1693.

91. McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl. 1989. 356:70–72. discussion 73-74.

92. Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab. 1998. 83:3913–3919.

93. Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf). 2002. 57:363–370.

94. Kehely A, Bates PC, Frewer P, Birkett M, Blum WF, Mamessier P, Ezzat S, Ho KK, Lombardi G, Luger A, Marek J, Russell-Jones D, Sonksen P, Attanasio AF. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab. 2002. 87:1974–1949.

95. Koller EA, Green L, Gertner JM, Bost M, Malozowski SN. Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. J Clin Endocrinol Metab. 1998. 83:2380–2383.

96. Radetti G, Gentili L, Lepidi M. Comment on growth hormone therapy and retinal changes mimicking diabetic retinopathy. J Clin Endocrinol Metab. 2000. 85:923.

97. Malozowski S, Tanner LA, Wysowski D, Fleming GA. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N Engl J Med. 1993. 329:665–666.

98. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O'Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, Harman SM. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. Jama. 2002. 288:2282–2292.

99. Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, Russell-Jones DL. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol. 2002. 146:807–811.

100. Tuffli GA, Johanson A, Rundle AC, Allen DB. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. J Clin Endocrinol Metab. 1995. 80:1416–1422.

101. Fradkin JE, Mills JL, Schonberger LB, Wysowski DK, Thomson R, Durako SJ, Robison LL. Risk of leukemia after treatment with pituitary growth hormone. Jama. 1993. 270:2829–2832.

102. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet. 2002. 360:273–277.

103. Porretti S, Giavoli C, Ronchi C, Lombardi G, Zaccaria M, Valle D, Arosio M, Beck-Peccoz P. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab. 2002. 87:2042–2045.

104. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab. 1997. 82:550–555.

105. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999. 84:3956–3960.